Dr. Reddy’s Laboratories Ltd. has announced the launch of a novel gastrointestinal therapy in India, introducing a next-generation acid blocker to strengthen its branded portfolio in a market where nearly 40% of people are affected by acid-related conditions.
The Hyderabad-based pharmaceutical company has launched Tegoprazan, a potassium-competitive acid blocker (PCAB), under the brand name PCAB. According to the company, the therapy is indicated for erosive and non-erosive Gastroesophageal reflux disease (GERD) and gastric ulcers, offering faster onset and longer pH control compared to conventional treatments.
The launch follows Dr. Reddy’s 2022 exclusive licensing agreement with HK inno.N Corp. of South Korea to commercialize Tegoprazan in India and select emerging markets. The molecule has already been approved in 21 countries, including South Korea and China, and has completed Phase III trials in the United States.
“We are happy to launch Tegoprazan in India, reinforcing our commitment to innovation in gastrointestinal disease treatment — a key focus area for us,” said M.V. Ramana, chief executive officer for branded markets at Dr. Reddy’s.
“Our partnership with HK inno.N brings together complementary strengths to enhance patient access to an innovative molecule that addresses critical gaps in acid peptic disease management,” he added.
Acid peptic disorders affect about 38% of India’s population, highlighting the commercial potential of new therapies. In a multinational clinical trial conducted by Dr. Reddy’s across India, South Africa, and Russia, 99% of GERD patients on Tegoprazan achieved endoscopic healing by Week 8, according to the company.
Dal-Won Kwak, CEO of HK inno.N, said the launch marks a milestone for the PCAB class in India. “We hope Tegoprazan will establish itself as a leading innovative therapy and contribute meaningfully to the improvement of gastrointestinal care,” he stated.
The introduction of Tegoprazan expands Dr. Reddy’s established gastrointestinal portfolio, which already includes brands like Omez, Razo and Vono. The company has been increasing its branded generics and specialty offerings in India and emerging markets to offset pricing pressures in the US generics segment.